Robert Zeiser

Featured in: Favicon

wiley.com

nature.com Favicon

frontiersin.org Favicon

nejm.org

science.org Favicon

cell.com

thelancet.com Favicon

healio.com Favicon

futuremedicine.com Favicon

targetedonc.com + 1 more

Articles

Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma - Bone Marrow Transplantation

Dec 4, 2024 | nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more

AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease - Bone Marrow Transplantation

Nov 5, 2024 | nature.com | Zahra Mahmoudjafari |Robert Zeiser |Franco Locatelli |Gerard Socie

AbstractREACH2 and REACH3 were randomized, multicenter, open-label phase 3 studies comparing the selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib versus investigators’ choice of best available therapy (BAT) in steroid-refractory (SR) acute (REACH2) or chronic (REACH3) graft-versus-host disease (aGVHD/cGVHD).
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome - Nature Cancer

May 13, 2024 | nature.com | Robert Zeiser
Navigating Unmet Needs in SR/D cGvHD

Feb 7, 2024 | targetedonc.com | Robert Zeiser

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Future Therapies in cGvHD

Jan 31, 2024 | targetedonc.com | Robert Zeiser

Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.
Use of Subsequent Therapies in SR/D cGvHD

Jan 31, 2024 | targetedonc.com | Robert Zeiser

Use of Subsequent Therapies in SR/D cGvHDExperts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.
REACH3: Ruxolitinib in Steroid Refractory cGvHD

Jan 24, 2024 | targetedonc.com | Robert Zeiser

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
First line Treatment and Challenges in Chronic GvHD

Jan 24, 2024 | targetedonc.com | Robert Zeiser

First line Treatment and Challenges in Chronic GvHDExplore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.
Navigating GvHD: Overview and Differences between Acute and Chronic GvHD

Jan 17, 2024 | targetedonc.com | Robert Zeiser

Navigating GvHD: Overview and Differences between Acute and Chronic GvHDTwo experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.
Clinical Evolution of Treatment in Chronic Graft vs. Host Disease

Jan 17, 2024 | targetedonc.com | Robert Zeiser

Clinical Evolution of Treatment in Chronic Graft vs. Host DiseaseDr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.